VIVS · VivoSim Labs Inc
Price
Snapshot
50 fields · last close| Market Cap | $2.56M |
| P/E | — |
| Float | 16.14M |
| Beta | 1.67 |
| Volatility 30D | 82.5% |
| Exchange | NASDAQ |
| Sector | Biotechnology |
| Cap tier | Micro cap |
| Macro sensitivity | High |
| Clavix score | 33.2 |
| Price | 0.14 |
| Change | −6.18% |
| Prev Close | 0.15 |
| Open | 0.15 |
| Day Low | 0.14 |
| Day High | 0.15 |
| Avg Vol | 1 |
| Avg $ Vol | $194.7K |
| 52W High | 3.40 |
| 52W Low | 0.14 |
| 52W Pos | 0.1% |
| From High | −95.80% |
| From Low | +3.33% |
| Max DD 1Y | −95.08% |
| Spread | 0.10% |
| Liquidity | Thin |
| SMA 20 | −11.23% |
| SMA 50 | −33.49% |
| SMA 200 | −86.33% |
| RSI (14) | 37.7 |
| Vol 90D | 126.0% |
| Vol 1Y | 112.2% |
| 1Y Range | 0–3 |
| Daily bars | 386 |
| Perf Week | +4.46% |
| Perf Month | −24.62% |
| Perf Quarter | −53.86% |
| Perf Half Y | −89.21% |
| Perf Year | −93.55% |
| Perf YTD | −92.40% |
| Prev Day | −6.18% |
| Clavix | F |
| Debt / Eq | 0.00 |
| Curr Ratio | 2.38 |
| Int Cover | -257.0× |
| FCF Margin | — |
| Rev Growth | −9.0% |
| Profit | Unprofitable |
| Leverage | Low |
| Sector rank | 33 / 35 |
Clavix risk grade
regraded every trading dayVIVS grades F, 33.2 of 100. Steadiest on Sector Resilience (76), most exposed on Price Stability (1, weak). 2 of the 4 weighted dimensions sit above the Biotechnology median. Ranks 33 of 35 in Biotechnology by Clavix score.
How rough the ride is
| VIVS | Biotechnology median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 1.67 | 0.49 |
| 30-day realized volatilityannualized, from daily closes | 82.5% | 46.0% |
| Max drawdown, past yearworst peak-to-trough fall | −95.1% | — |
| Typical daily movemedian absolute daily change | 2.68% | — |
| Days beyond ±3%of the last 252 sessions | 121 (48%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| VIVS | Biotechnology median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 1.67 | 0.49 |
| Macro sensitivityrate, dollar and credit exposure bucket | High | Low 54% of 35 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Biotechnology names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| VIVS | |
|---|---|
| 1 week | +4.5% |
| 1 month | −24.6% |
| Year to date | −92.4% |
| 1 year | −93.6% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| VIVS | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 29 since 12 Feb |
| Average score0 most bearish, 100 most bullish | 62 |
| Bullish · bearisharticles above 60 · below 40 | 22 · 6 |
| Directionarticles whose tone is improving vs worsening | 22 ↑ 6 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 35 Biotechnology names Clavix covers; the tick is the sector median.
Growth
| VIVS | |
|---|---|
| Revenue growthyear over year | −9.0% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Biotechnology median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openVivoSim Labs and Chemveda Life Sciences announced a collaboration in which Chemveda designs and manufactures drug molecules and VivoSim’s NAMkind 3D human liver and intestine models identify which candidates should advance toward human testing. The announcement says the safety-screening process can take weeks rather than years.
VivoSim Labs announced that it is expanding its NAMkind platform beyond toxicology with patient-derived human liver and intestinal disease models. The models are intended to test whether drug candidates reduce disease in human tissue before clinical trials and to profile the biological mechanisms behind treatment effects.
VivoSim Labs extended its NAMkind platform with patient-derived human liver and intestinal disease models. The models are intended to help drug developers test whether a candidate reduces disease in human tissue before clinical trials and to measure biological markers that help explain how a treatment works.
VivoSim Labs (VIVS) announced it is celebrating updated FDA rules that allow greater use of non-animal safety testing methods, noting its human-relevant testing models are already helping reduce drug development costs.
VivoSim Labs is highlighting updated FDA regulations that permit greater use of non-animal safety testing methods, noting that its human-relevant testing models are already positioned to help lower drug development costs.
Nearest peers by size
Biotechnology| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| ERNA | Ernexa Therapeutics Inc | F | $3.25M | — | 2.79 | Compare |
| QTTB | Q32 Bio Inc. | F | $267.0M | 8.88 | 0.59 | Compare |
| CELC | Celcuity Inc. | C+ | $3.39B | — | 0.19 | Compare |
| IOVA | Iovance Biotherapeutics Inc | D- | $3.94B | — | 0.84 | Compare |
| ERAS | Erasca, Inc. | C | $5.21B | — | 0.66 | Compare |
| PTCT | PTC Therapeutics, Inc. | B | $5.76B | 8.34 | 0.49 | Compare |
| CGON | CG Oncology, Inc. | B- | $6.00B | — | 0.32 | Compare |
| IONS | Ionis Pharmaceuticals, Inc. | B- | $6.67B | — | 0.36 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.